For a woman whose eating is stress-driven, the GLP-1 alone will not land
The application of SFN significantly protected cutaneous inflammation in an NRF2-dependent manner
In fact, it was designed to avoid the appetite stimulation seen with some earlier peptides
Medicare does still cover GLP-1 medications when they are prescribed for approved indications such as type 2 diabetes or, in some cases, cardiovascular disease risk reduction
And as you said, being patient and going slowly as well
Future studies should focus on refining experimental models, integrating multi-omics approaches, and establishing standardized assessment systems to enhance the clinical relevance of preclinical findings and facilitate the translation of novel therapeutic strategies into practice